Pancreatic Cancer Research

ResearcherUniversity of CambridgeActive in the last 2 years

Bristi Basu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3562-2868; OpenAlex author ID A5017721654. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 2, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 trial · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis. Co-author DOI 10.1038/s41556-026-02057-w↗
  2. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02170-9↗
  3. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  4. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. First author DOI 10.1038/s41467-020-18636-w↗
  5. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1038/bjc.2017.495↗
  6. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Co-author DOI 10.1016/s2468-1253(16)30079-6↗
  7. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Last author DOI 10.1159/000439171↗
  8. Progress in pancreatic cancer: moving beyond gemcitabine? Co-author DOI 10.1586/era.12.78↗

Trials 1

  1. Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) Principal investigator NCT02124369↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Duncan Ian Jodrell · 4 shared papers, 2012–2023 · strength 0.37
  2. Pippa G. Corrie · 3 shared papers, 2015–2023 · strength 0.30
  3. Rebecca J. Brais · 2 shared papers, 2020–2026 · strength 0.29
  4. Alimu Dayimu · 2 shared papers, 2020–2023 · strength 0.24
  5. Juan W. Valle · 2 shared papers, 2020–2023 · strength 0.24
  6. David J. Propper · 3 shared papers, 2018–2020 · strength 0.22
  7. Joaquín Araos Henríquez · 1 shared paper, 2026 · strength 0.22
  8. Priscilla S.W. Cheng · 1 shared paper, 2026 · strength 0.22
  9. Eloise G. Lloyd · 1 shared paper, 2026 · strength 0.22
  10. Wenlong Li · 1 shared paper, 2026 · strength 0.22
  11. Gianluca Mucciolo · 1 shared paper, 2026 · strength 0.22
  12. Giulia Biffi · 1 shared paper, 2026 · strength 0.22
  13. Alan Anthoney · 2 shared papers, 2018–2020 · strength 0.14
  14. Daniel H. Palmer · 2 shared papers, 2018–2020 · strength 0.14
  15. Aarthi Gopinathan · 2 shared papers, 2018–2020 · strength 0.14
  16. David Arthur Tuveson · 2 shared papers, 2018–2020 · strength 0.14
  17. Michelle Rodriques Goulart · 1 shared paper, 2020 · strength 0.08
  18. Christine Hughes · 1 shared paper, 2020 · strength 0.08
  19. Fieke E. M. Froeling · 1 shared paper, 2020 · strength 0.08
  20. Debashis Sarker · 1 shared paper, 2020 · strength 0.08
  21. Hemant Mahendrakumar Kocher · 1 shared paper, 2020 · strength 0.08
  22. Albrecht Neeße · 1 shared paper, 2020 · strength 0.07
  23. Harpreet Singh Wasan · 1 shared paper, 2020 · strength 0.07
  24. Natalie Cook · 1 shared paper, 2018 · strength 0.06
  25. Ehsan Ghorani · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.